baber/WOPTO huggingface dataset:
Patent NZ-512128-A (NZ)
Title: Methods for controlling or treating helminth and arthropod endoparasite or ectoparasite insect infection by oral, topical or transdermal means
Inventor: PRICHARD ROGER K
IPC: A61K31/365
Filed: 1998-04-29
Abstract: A method for increasing the efficacy of a monocyclic lactone compound against a resistant crop pest is described.  The method comprises application of a pesticidal enhancing effective amount of a multidrug resistance reversing (MDR) agent and the monocyclic lactone compound, wherein the multidrug resistance reversing agent is selected from the group consisting of a calcium channel blocker, a calmodulin antagonist, a vinca alkaloid analogue, a steroidal agent, a hormonal agent, an immunosuppressive agent, an antibiotic and dispyridamole. Also described is a method for increasing the efficacy of a monocyclic lactone compound against a resistant arthropod or nematode ectoparasites or endoparasites in a non-human mammal using the multidrug resistance reversing agents mentioned above.
Patent NZ-513148-A (NZ)
Title: The use of certain affinity NMDA antagonists as antidepressants
Inventor: MCCARTHY DENNIS
IPC: A61K31/166
Filed: 2000-03-21
Abstract: Described is the use of a low affinity NMDA antagonist of the formula (I) in the manufacture of a medicament for the treatment or prophylaxis of depression. In the compound of formula (I): R1 is pyridyl, phenyl or 4 fluorophenyl; R2 is phenyl or 4 flurophenyl; R3 is hydrogen, C1-6alkyl or methoxycarbonyl; R4 is hydrogen or methyl; and R5 is hydrogen or COCH2NH2
Patent NZ-515242-A (NZ)
Title: 1-(p-Thienylbenzyl)-imidazoles as angiotensin-(1-7) receptor agonists, method for the production and the utilization thereof and pharmaceutical preparations containing said compounds
Inventor: HEITSCH HOLGER
IPC: C07D409/10
Filed: 2000-04-29
Abstract: A compound of formula (I), where: R(1) is halogen; hydroxyl; (C1-C4)alkoxy; (C1-C8)alkoxy, wherein 1 to 6 carbon atoms are replaced by the heteroatoms O, S, or NH, (C1-C4)-alkoxy, substituted by a saturated cyclic ether; O-(C1-C4)-alkenyl; O-(C1-C4)-alkylaryl; or phenoxy, unsubstituted or substituted by a substituent selected from halogen, (C1-C3)-alkyl, (C1-C3)-alkoxy, and trifluoromethyl; R(2) is CHO; COOH; or CO-O-(C1-C4)-alkyl; R(3) is (C1-C4)-alkyl; or aryl; R(4) is hydrogen; halogen; or (C1-C4)-alkyl; X is oxygen or sulfur; Y is oxygen or -NH-; R(5) is hydrogen; (C1-C6)-alkyl; or (C1-C4)-alkylaryl; where R(5) can only be hydrogen if Y is -NH-; and R(6) is (C1-C5)-alkyl with the proviso that compounds of the formula (I) in which R(1) is halogen and R(2) is COOH or CO-O-(C1-C4)-alkyl are excluded. Also described is a pharmaceutical preparation comprising the compound of formula (I). The compounds of formula (I) as defined above (but where the proviso restricting the values of R(1) and R(2) described above does not apply) are useful for the treatment and/or prophylaxis of illnesses which are primarily or secondarily caused or at least partly caused by reduced production and/or release of the vasorelaxant, antithrombotic and cardioprotective messengers cyclic 3',5'-guanosine monophosphate (cGMP) and nitrogen monoxide (NO).
Patent NZ-515279-A (NZ)
Title: Novel 8a- and 9a-15-membered lactams
Inventor: LAZAREVSKI GORJANA
IPC: A61P31/04
Filed: 2000-04-19
Abstract: 15-membered 8a- and 9a-lactams from the class of 6-O-methyl-erythromycin A of the general formula (I), their pharmaceutically acceptable addition salts with inorganic or organic acids and their hydrates wherein: A is NH and B is C=O, or B is NH and A is C=O; R1 is selected from the list consisting of an OH group, a group of formula (II) or (III) or R1 together with R2 is a ketone; R2 is hydrogen or forms the aforementioned ketone with R1; R3 is hydrogen or an alkanoyl group; R4 is hydrogen or together with R5 is a ketone; R5 is selected from the list consisting of OH, NH2, aminoalkyl, aminodialkyl, O(CH2)nAr or forms the aforementioned ketone with R4; R6 is selected from the list consisting of hydrogen, alkyl, an alkyl group with at least one incorporated atom selected from the list consisting of O, N and S, (CH2)nAr or R5 and R6 together with intervening atoms form an additional ring of formula (IVa) or (IVb); with the following exclusions; when R5 is OH, R1 does not stand for the group of formula (II) and when R6 stands for H, R1 does not stand for the group of formula (II).
Patent NZ-518219-A (NZ)
Title: Method for operating a conditional access system for broadcast applications
Inventor: WAJS ANDREW AUGUSTINE
IPC: H04H20/00
Filed: 2000-10-04
Abstract: To operate the conditional access system of a broadcast application, entitlement management messages (EMM's) are sent to one or several secure devices (12) of the subscriber's terminals (10) that serve to store entitlements. The sent EMM's each provide an entitlement and an expiry date of the entitlement. The entitlements are refreshed periodically in accordance with their expiry dates by sending EMM's updating the expiry dates, but this can take considerable time for many subscribers. To extend the time, a set of extension EMM's is sent to at least some of all of the secure devices (12), each extension EMM indicating that all entitlements having an expiry date within a predetermined first period are extended by a predetermined second period. Then EMM's updating the expiry dates are sent after the extension EMM's have been sent.
Patent NZ-519884-A (NZ)
Title: New diazepine carboxamide derivatives, their preparation process, their use as medicaments, pharmaceutical compositions and their new use
Inventor: BHATNAGAR NEERJA
IPC: C07D487/04
Filed: 2000-12-21
Abstract: A compound of formula (I); a process for the preparation of the compound; a medicament comprising the compound; a pharmaceutical composition containing as an active ingredient the medicament; and the use of the compound for the preparation of a medicament for the prevention or treatment of disease in which metabolic enzymes such as proteases or kinases such as cathepsin K, cathepsin B or papain are involved wherein the diseases may be chosen from cardiovascular diseases cancers, diseases of the central nervous system, inflammatory diseases, infectious diseases or bone diseases.
Patent NZ-521591-A (NZ)
Title: Oxidising treatment of a fibrous textile mass such as wool that can be given in the form of a web capable of being traversed homogeneously by a gas such as ozone and/or oxygen
Inventor: CHOISNARD LUC
IPC: D06M16/00
Filed: 2001-03-28
Abstract: A method for oxidising a textile mass is described, in particular woollen, to modify the surface of the fibres whereof it is formed, consisting of: a) transforming said textile mass into a textile mass containing 12.5 to 60 % (g/g) of water and having a structure such that a gas can pass through it uniformly and thoroughly; and b) passing through the mass, for 5 to 20 minutes at room temperature, a gas mixture containing 20 to 150g of ozone per m3, which is continuously injected through the mass while it moves along on a carrier system, being alternately directed on both surfaces of each pass. Such treatment is preferably carried out in a sealed chamber, the ozone being destroyed in output.
Patent NZ-523439-A (NZ)
Title: Particle entrapment system
Inventor: BROWN COLIN W
IPC: A47L13/17
Filed: 2001-06-22
Abstract: A cleaning sheet for cleaning and removing particles from a surface is disclosed. The sheet includes a particle retention layer including an electret material for collecting and retaining the particles. The sheet also includes an outer layer covering at least a portion of the particle retention layer. The outer layer comprises a low dust retention material and includes a surface having a plurality of apertures formed there through
Patent NZ-526617-A (NZ)
Title: Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
Inventor: GILLIS KIMBERLY A
IPC: C12Q1/68
Filed: 2001-11-28
Abstract: A method of assessing whether a subject is afflicted by prostate cancer, the method comprising comparing: - The level of expression of a marker in a sample from a subject, wherein the marker is selected form the group consisting of one or more KIAA markers and - The normal level of expression of the marker in a control sample, wherein a significant difference between the level of expression of the marker in the sample form the subject and the normal level is an indication that the subject is afflicted with prostate cancer. The use of an antisense oligonucleotide complimentary to a polynucleotide corresponding to a KIAA 18 marker is also described as being useful in the manufacture of a medicament for the treatment of prostate cancer.
Patent NZ-532956-A (NZ)
Title: Smoking articles with reduced ignition proclivity characteristics of paper wrappers
Inventor: KRAKER THOMAS A
IPC: A24D1/02
Filed: 2003-01-20
Abstract: A process for reducing the permeability of a paper wrapper 14 used in the construction of a smoking article 10 is disclosed. The paper wrapper 14 is treated with a film-forming composition that forms treated discrete areas 18 on the wrapper 14. The treated discrete areas 18 have a permeability within a predetermined range sufficient to reduce the ignition proclivity properties of a smoking article 10 made with the wrapper 14. The film-forming composition contains a film-forming material such as sodium alginate and other film-forming materials selected from the group consisting of guar gum, pectin, polyvinyl alcohol, a cellulose derivative, starch, a starch derivative, and mixtures thereof. The treated areas 18 may further comprise a citrate. The film-forming material has a relatively low viscosity. In this manner, the film-forming composition can have a relatively high solids content and still be applied to the wrapper using conventional techniques, such as by using a gravure printer.
Patent NZ-533594-A (NZ)
Title: A method for determining the biological activity of defibrotide
Inventor: PORTA ROBERTO
IPC: C12Q1/68
Filed: 2002-11-27
Abstract: Disclosed is a method for determining the biological activity of defibrotide, which comprises the steps of: a) bringing into contact defibrotide, plasmin and a substrate specific for the plasmin which, by reaction with the plasmin, provides a measurable product, and b) measuring the amount of product formed at successive times, wherein the substrate specific for the plasmin is a compound of formula A1-A2-A3-X in which A1 and A2 are non-polar amino acids, A3 is lysine or arginine and X is the measurable product, and where the concentration of the substrate for the plasmin is from 0.3 to 3.5mM.
Patent NZ-535408-A (NZ)
Title: Method for selecting prodrugs of phosphonate nucleotide analogues
Inventor: ROHLOFF JOHN C
IPC: C07H19/10
Filed: 2001-07-20
Abstract: A screening method for identifying a methoxyphosphonate nucleotide analogue prodrug conferring enhanced activity in a target tissue comprising: (a) providing at least one of the prodrugs, (b) selecting at least one therapeutic target tissue and at least one non-target tissue, (c) administering the prodrug to the target tissue and to the at least one non-target tissue, and (d) determining the relative activity conferred by the prodrug in the tissues in step (c),wherein the method is not a surgical method performed on a human body.
Patent NZ-540667-A (NZ)
Title: A method of preventing and/or treating asthma using parabromophenacyl bromide (PBPB)
Inventor: RAM ARJUN
Filed: 2002-12-02
Abstract: Disclosed is a use of an effective pharmacological amount of parabromophenacyl bromide (PBPB) in the manufacture of a medicament for preventing and/or treating asthma in a subject which may be achieved by modulating levels of biomolecules to a subject. Also described in the specification is a method of preventing and/or treating asthma in a subject is disclosed, said method comprising step of administering effective pharmacological amount of parabromophenacyl bromide (PBPB) to the subject and a method of modulating levels of biomolecules to achieve the same.
Patent NZ-541533-A (NZ)
Title: Liquid pharmaceutical formulations of palonosetron
Inventor: CALDERARI GIORGIO
IPC: A61K31/4747
Filed: 2004-01-30
Abstract: Disclosed is a pharmaceutically stable solution for preventing or reducing emesis comprising from about 0.03 mg/mL to about 0.2 mg/mL palonosetron or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier; wherein the pH is about 4.0 to about 6.0.
Patent NZ-544366-A (NZ)
Title: Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications
Inventor: OLSHENITSKY MARK
Filed: 2001-11-27
Abstract: The use of a formulation comprising at least one volatile fraction (VF) of a plant extract, said plant extract is obtained by water extraction and said volatile fraction being prepared by steam distillation of said plant extract under a pressure lower than atmospheric pressure and at a bath temperature not exceeding 38 degrees C; to sustain viability of as much as 107 cells/ml of at least one microorganism for at least two months at room temperature, with the proviso that said microorganism is not Escherichia coli strain BU-230-98 ATCC Deposit No. 202226 (DSM 12799). Also disclosed are dispensers for said formulation and methods of using said formulation.
Patent NZ-548318-A (NZ)
Title: Sulfonamide derivatives for the treatment of diseases
Inventor: BROWN ALAN DANIEL
IPC: C07D217/06
Filed: 2005-01-12
Abstract: Disclosed is a compound of formula (I), and pharmaceutically acceptable salts, isomers, tautomers, solvates and isotopic variations thereof, where n is 0, 1, or 2, Q is a nitrogen attached to a ring system as described, and wherein the rest of the subtituents are disclosed in the specification. Also disclosed is a process for the preparation of such a compound. Also disclosed is the suitability of the above compound for treating diseases involving the â2 receptor (beta2 receptor), and specifically: asthma of whatever type, chronic or acute cronchoconstriction, chronic bronchitis, small airways obstruction, emphysema, obstructive or inflammatory airways diseases of whatever type, including chronic eosinophilic pneumonia, chronic obstructive pulmonary disease (COPD), COPD that includes chronic bronchitis, pulmonary emphysema or dyspnea associated or not associated with COPD, COPD that is characterized by irreversible, progressive airways obstruction, adult respiratory distress syndrome (ARDS), exacerbation of airways hyperreactivity consequent to other drug therapy and airways disease that is associated with pulmonary hypertension, bronchitis of whatever type, in particular bronchitis that is a member selected from the group consisting of acute bronchitis, acute laryngotracheal bronchitis, arachidic bronchitis, catarrhal bronchitis, croupus bronchitis, dry bronchitis,infectious asthmatic bronchitis, productive bronchitis, staphylococcus or streptococcal bronchitis and vesicular bronchitis, acute lung injury, bronchiectasis of whatever type, in particular bronchiectasis that is a member selected from the group consisting of cylindric bronchiectasis, sacculated bronchiectasis, fusiform bronchiectasis, capillary bronchiectasis, cystic bronchiectasis, dry bronchiectasis and follicular bronchiectasis.
Patent NZ-549360-A (NZ)
Title: Beverage cooler
Inventor: CHIUSOLO SAM
Filed: 2002-06-19
Abstract: An apparatus for cooling a carbonated beverage, stored in a container, and dispensing a non-foamed carbonated beverage is disclosed. The apparatus comprises: (a) a housing defining a chamber having first and second openings; (b) a pressurizing means attached to the container for maintaining the beverage under pressure in the container; (c) a conduit located in the chamber, where the conduit communicates with the container through the first opening, and the conduit further communicates with the second opening for delivering the beverage from the chamber; (d) a perforated vessel mounted in the chamber, where the perforated vessel surrounds the conduit; (e) cooling fluid located in the chamber for cooling the conduit, where the cooling fluid includes solid fragments which are substantially larger than the perforations in the vessel; (f) an agitator for circulating the cooling fluid over the conduit; and (g) a pressure valve located between the conduit and the container for detecting a predetermined pressure rating in the container.
Patent NZ-552391-A (NZ)
Title: Monolithic vertical junction field effect transistor and schottky barrier diode fabricated from silicon carbide and method for fabricating the same
Inventor: MAZZZOLA MICHAEL S
IPC: H01L29/15
Filed: 2005-07-08
Abstract: A switching element combining a self-aligned, vertical junction field effect transistor with etched-implanted gate and an integrated anti-parallel Schottky barrier diode is disclosed. The anode of the diode is connected to the source of the transistor at the device level in order to reduce losses due to stray inductances. The SiC surface in the Schottky barrier diode anode region is conditioned through dry etching to achieve a low Schottky barrier height so as to reduce power losses associated with the turn on voltage of the Schottky barrier diode.
Patent NZ-560204-A (NZ)
Title: Crystalline forms of (1RS,3RS,6RS)-6-dimethylaminomethyl-1-(3-methoxy- phenyl)cyclohexane-1,3-diol hydrochloride
Inventor: GRUSS MICHAEL
IPC: A61K31/135
Filed: 2006-02-21
Abstract: Solid crystalline forms of (1 RS,3RS,6RS)-6- Dimethylaminomethyl-1-(3-methoxy-phenyl)cyclohexane-1 ,3-diol hydrochloride (1), methods of producing 1, methods of use of 1, use of 1 as analgesics and pharmaceutical compositions comprising 1.
Patent NZ-560716-A (NZ)
Title: Networking hardware element to couple computer network elements and method of displaying thereon
Inventor: PHAM ANTHONY
Filed: 2007-08-17
Abstract: A networking hardware element to couple together computer network elements comprises: one or more transceivers configured to receive communication signals from one or more of the computer network elements and to forward the communication signals to one or more different ones of the computer network elements; a network diagnostic mechanism capable of monitoring the computer network elements to determine network information by iteratively scanning the transceivers; and an electronic display at a surface of the networking hardware element and electrically coupled to the network diagnostic mechanism, the electronic display capable of displaying at least a network layout map as part of the network information; and displaying additional information.
Patent NZ-564255-A (NZ)
Title: Novel heterocyclic compounds as positive allosteric modulators of metabotropic glutamate receptors
Inventor: FARINA MARCO
IPC: A61K31/4439
Filed: 2006-05-17
Abstract: Disclosed herein are substituted oxadiazole compounds of formula (I-D), wherein the substituents are as defined within the specification, as positive allosteric modulators of metabotropic receptors - subtype 5 ('mGluR5') which are useful for the treatment or prevention of central nervous system disorders such as for example, cognitive decline, both positive and negative symptoms in schizophrenia as well as other central or peripheral nervous system disorders in which the mGluR5 subtype of glutamate metabotropic receptor is involved. The invention is also directed to pharmaceutical compounds and compositions in the prevention or treatment of such diseases in which mGluR5 is involved.
Patent NZ-564294-A (NZ)
Title: A method and a prebaked anode for aluminium production
Inventor: STORESUND ARILD
IPC: C25C3/12
Filed: 2006-06-09
Abstract: Disclosed is a prebaked anode for a Hall-Héroult cell for production of aluminium, the anode having one or more slots arranged in its wear surface at the bottom for gas drainage, characterised in that said one or more slots are of 2-8 millimetres width. Also disclosed is a method of producing aluminium in an Hall-Héroult cell with prebaked anodes, using the anodes as above.
Patent NZ-569369-A (NZ)
Title: Tear resistant bag using a opening defined by peaks and valleys where the peaks tie together to close the bag
Inventor: RUSNAK JOHN
IPC: B65D33/16
Filed: 2006-12-11
Abstract: A tie bag (300) resistant to tearing is disclosed. The bag (300) includes an undulating top edge (304) defining an opening to the bag (300). The top edge (304) includes at least two flaps (306, 308, 310, 312) and at least two valleys (326, 328, 330, 332). In one embodiment, a valley (326, 328, 330, 332) may include a flat portion at the bottom of the valley (326, 328, 330, 332). The flaps (306, 308, 310, 312) can be tied together to at least partially close the bag (300). The bag (300) also includes a first seam (346) that intersects the flat portion of a valley (326, 328, 330, 332). The flat portion reduces the possibility of tearing the seam (346). The valley also includes a slit (334) to act to stop the initiation of a tear at the seam.
Patent NZ-572044-A (NZ)
Title: Bypass type follower assembly having a latch mechanism on the follower claw
Inventor: JOHNSON MICHAEL P
IPC: B27F7/13
Filed: 2007-03-26
Abstract: A bypass type follower mechanism adapted to be disposed within a magazine of a fastener-driving tool and a fastener driving tool comprising said follower mechanism. The follower mechanism is used to bias a supply of fasteners toward a position in which the leading fasteners can be serially discharged from the fastener-driving tool. The mechanism comprises a follower body (12) adapted to be movably disposed within the magazine, a follower claw (24) for engaging at least the trailing fastener to bias the fasteners toward a forward position and a means (40) for pivotally mounting the follower claw (24) upon the follower body (12). The follower claw is pivotal between a first position at which the claw engages at least the trailing fastener and a second position at which the claw can bypass the supply of fasteners. A latch hook means (42) is mounted upon the follower claw for engaging a rear section of the fastener magazine to retain the follower mechanism in a rearward region of the magazine.
Patent NZ-576112-A (NZ)
Title: Flying insect trap with spaced entryways
Inventor: SCHNEIDMILLER RODNEY G
IPC: A01M1/02
Filed: 2008-08-28
Abstract: An insect trap (100) is disclosed comprising an entrapment chamber (110) having a first compartment (102) disposed over a second compartment (104) and a transverse wall (106) separating the first compartment (102) from the second compartment (104). The entrapment chamber (110) has an open first distal end (112) and an open second distal end (114). A first entry structure is removably attached to the open first distal end of the entrapment chamber defining a first plurality of entry apertures (126) for insect access directly to the first compartment. A second entry structure (140) is removably attached to the open second distal end (114) of the entrapment chamber (110) defining a second plurality of entry apertures (146) for insect access directly to the second compartment (104). A further embodiment discloses such a trap with a plurality of compartments each having a conical tapered guide (128, 148) disposed over the entry aperture of the compartment.
Patent NZ-576797-A (NZ)
Title: Arabinose isomerase expressed from corynebacterium genus and tagatose manufacturing method by using it
Inventor: CHOI HYE-JIN
IPC: C12N9/90
Filed: 2007-11-08
Abstract: Disclosed is a method for producing an arabinose isomerase including the steps of: a) preparing a recombinant vector by inserting a gene encoding a thermophilic arabinose isomerase, which has the amino acid sequence of SEQ ID NO:3 originating from the Thermotoga neapolitana DSM 5068, into the shuttle vector pCJ-l(KCCM 10611P) or pCJ-7(KCCM 10617P); and b) transfecting a Corynebacterium sp. strain with the recombinant vector; and c) producing the arabinose isomerase by culturing the Corynebacterium sp. strain.